MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.74 6.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.55

Max

2.74

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+389.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	36M 583M
Eelmine avamishind	-3.87
Eelmine sulgemishind	2.74

Uudiste sentiment

By Acuity

60%

40%

312 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. jaan 2026, 23:43 UTC

Market Talk

Gold Consolidates; May Face Technical Correction -- Market Talk

20. jaan 2026, 23:42 UTC

Market Talk

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20. jaan 2026, 23:41 UTC

Tulu

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20. jaan 2026, 23:29 UTC

Market Talk

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20. jaan 2026, 23:26 UTC

Market Talk

Global Equities Roundup: Market Talk

20. jaan 2026, 23:26 UTC

Market Talk

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20. jaan 2026, 22:45 UTC

Omandamised, ülevõtmised, äriostud

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20. jaan 2026, 22:45 UTC

Omandamised, ülevõtmised, äriostud

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20. jaan 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20. jaan 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20. jaan 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20. jaan 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20. jaan 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20. jaan 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20. jaan 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20. jaan 2026, 22:18 UTC

Tulu

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20. jaan 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20. jaan 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20. jaan 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20. jaan 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20. jaan 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20. jaan 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20. jaan 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20. jaan 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20. jaan 2026, 22:07 UTC

Omandamised, ülevõtmised, äriostud

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20. jaan 2026, 22:06 UTC

Tulu

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20. jaan 2026, 22:00 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ESG Roundup: Market Talk

20. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

389.29% tõus

12 kuu keskmine prognoos

Keskmine 12.33 USD 389.29%

Kõrge 15 USD

Madal 10 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

312 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.